Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bridges

Showing results (571-580 of 588) with videos related to

Pageof 59
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2024
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosisHermann Bihler, Andrey Sivachenko, Linda Millen, et al.
The American Journal of Tropical Medicine and Hygiene|July 4, 2020
Evidence for Reduced Malaria Parasite Population after Application of Population-Level Antimalarial Drug Strategies in Southern Province, ZambiaRachel F Daniels, Stephen F Schaffner, Adam Bennett, et al.
BMJ Open|August 18, 2021
Adverse events associated with endoscopic retrograde cholangiopancreatography: protocol for a systematic review and meta-analysisNauzer Forbes, Grigorios I Leontiadis, Marcus Vaska, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
MMWR. Morbidity and Mortality Weekly Report|February 25, 2021
Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020Mulenga Mwenda, Ngonda Saasa, Nyambe Sinyange, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901Stephen D Barrett, Alexander J Bridges, David T Dudley, et al.
JCI Insight|March 22, 2022
CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftorKaren S Raraigh, Kathleen C Paul, Jennifer L Goralski, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Gastroenterology|November 8, 2024
Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-AnalysisKirles Bishay, Zhao Wu Meng, Rishad Khan, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 59

Showing results (571-580 of 588) with videos related to

Sort By:
Pageof 59
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2024
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosisHermann Bihler, Andrey Sivachenko, Linda Millen, et al.
The American Journal of Tropical Medicine and Hygiene|July 4, 2020
Evidence for Reduced Malaria Parasite Population after Application of Population-Level Antimalarial Drug Strategies in Southern Province, ZambiaRachel F Daniels, Stephen F Schaffner, Adam Bennett, et al.
BMJ Open|August 18, 2021
Adverse events associated with endoscopic retrograde cholangiopancreatography: protocol for a systematic review and meta-analysisNauzer Forbes, Grigorios I Leontiadis, Marcus Vaska, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
MMWR. Morbidity and Mortality Weekly Report|February 25, 2021
Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020Mulenga Mwenda, Ngonda Saasa, Nyambe Sinyange, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901Stephen D Barrett, Alexander J Bridges, David T Dudley, et al.
JCI Insight|March 22, 2022
CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftorKaren S Raraigh, Kathleen C Paul, Jennifer L Goralski, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Gastroenterology|November 8, 2024
Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-AnalysisKirles Bishay, Zhao Wu Meng, Rishad Khan, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 59